Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal

Acelyrin, backed with more than $550 million in venture capital, adds to drug pipeline with acquisition.

Thursday, January 5, 2023 at 10:00 am

Full Coverage